Folkert W. Visser

Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial

Arjan J. Kwakernaak, Jan A. Krikken, S. Heleen Binnenmars et al. · The Lancet Diabetes & Endocrinology · 2014 · 114 citations

Pharmacy, Nephrology, Pharmacotherapy +13

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease

Esther Meijer, Folkert W. Visser, R. Aerts et al. · JAMA · 2018 · 107 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

R. Aerts, Wietske Kievit, Hedwig M. A. D‘Agnolo et al. · Gastroenterology · 2019 · 83 citations · Full text

Medicine, Genetics, Internal Medicine +12

Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Esther Meijer, Joost P.H. Drenth, Hedwig M. A. D‘Agnolo et al. · American Journal of Kidney Diseases · 2013 · 70 citations · Full text

Medicine, Nephrology, Pharmacotherapy +9

Feasibility and Impact of the Measurement of Extracellular Fluid Volume Simultaneous with GFR by 125I-Iothalamate

Folkert W. Visser, J.H.J. Muntinga, Rudi Dierckx et al. · Clinical Journal of the American Society of Nephrology · 2008 · 53 citations · Full text

Medicine, Nephrology, Physiology +17